Clinical pharmacokinetics of mirtazapine

Clinical Pharmacokinetics

Volumn 38, Issue 6, 2000, Pages 461-474

  Timmer, Cees J ^a   Ad Sitsen, J M ^a   Delbressine, Leon P ^a  

^a NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CIMETIDINE; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DIAZEPAM; FLUOXETINE; LITHIUM; MIRTAZAPINE; PAROXETINE; PLASMA PROTEIN; RISPERIDONE; SEROTONIN AGONIST;

AGE; AREA UNDER THE CURVE; BIOTRANSFORMATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; ENANTIOMER; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GASTROINTESTINAL ABSORPTION; GENDER; GENETIC POLYMORPHISM; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LIVER METABOLISM; PRIORITY JOURNAL; RACEMIC MIXTURE; REVIEW; STEREOCHEMISTRY;

EID: 0034098297     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200038060-00001     Document Type: Review

References (56)

1. 2-antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol 1994; 253: R5-6
2. 1A-mediated serotonergic neurotransmission. CNS Drugs 1995; 4 Suppl. 1: 29-38
3. 3. De Montigny C, Haddjeri N, Mongeau R, et al. The effects of mirtazapine on interactions between central noradrenergic and serotonergic systems. CNS Drugs 1995; 4 Suppl. 1: 13-17
4. 4. Bremner JD. A double-blind comparison of Org 3770, amitriptyline and placebo in major depression. J Clin Psychiatry 1995; 56: 519-25
5. 5. Claghorn JL, Lessem MD. A double-blind placebo controlled study of Org 3770 in depressed outpatients. J Affective Disorders 1995; 34: 165-71
6. 6. Sitsen JMA, Zivkov M, Dieterle D. Wirksamkeit under Verträglichkeit von Org 3770 bei Patienten mit einer Major Depression. Psychopharmakotherapie 1995; 2: 68-71
7. 7. Van Moffaert M, De Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a controlled study in hospitalised patients with major depression. Int Clin Psychopharmacol 1995; 10: 3-9
8. 8. Wheatley DP, Van Moffaert M, Timmerman L, et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatr 1998; 59: 306-12
9. 9. Zivkov M, De Jongh G. Org 3770 vs amitriptyline: a 6-week randomised double-blind multicentre trial in hospitalised patients. Hum Psychopharmacol 1995; 10: 263-71
10. 10. Mullin J, Lodge A, Bennie E, et al. A multicentre double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. J Psychopharmacol 1996; 10: 235-40
11. 11. Richou H, Ruimy P, Charbaut J, et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995; 10: 263-71
12. 12. Marttilla M, Jääskeläinen J, Järvi R, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1995; 5: 441-6
13. 13. Montgomery SA. Clinically relevant sizes in depression. Eur Neuropsychopharmacol 1994; 4: 283-4
14. 14. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol 1999; 14: 329-37
15. 15. Thompson C. Mirtazapine versus selective serotonin reuptake inhibitors. J Clin Psychiatry 1999; 60 Suppl. 17: 18-22
16. 16. Montgomery SA. New developments in the treatment of depression. J Clin Psychiatry 1999; 60 Suppl. 14: 19-5
17. 17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
18. 18. Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 1995; 10 Suppl. 2: S125-33
19. 19. Hoeyberg OJ, Maragakis B, Mullin J, et al. A double blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand 1996; 93: 184-90
20. 20. Cohen M, Panagides J, Timmer CJ, et al. Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal. Eur J Drug Metab Pharmacokinet 1997; 22: 103-10
21. 21. Colbers EPH, Boom SPA, Kleijn HJ, et al. Single-dose, fasting, open, randomised, two-way cross-over bioequivalence study on Org 3770 oral liquid versus 15 mg tablet in thirty-two healthy volunteer subjects [Study 22523, Report No. NL 0012550]. Oss: N.V. Organon, 1999. (Data on file)
22. 22. Voortman G, Paanakker JE. Bioavailability of mirtazapine from Remeron® tablets after single and multiple oral dosing. Hum Psychopharmacol 1995; 10 Suppl.: S83-96
23. 23. Bengtsson F, Höglund P, Timmer C, et al. Mirtazapine oral single dose kinetics in patients with different degrees of renal failure. Hum Psychopharmacol 1998; 13: 357-65
24. 24. Murdoch DL, Ashgar J, Ankier SI, et al. Influence of hepatic impairment on the pharmacokinetics of single doses of mirtazapine in elderly subjects [abstract]. Br J Clin Pharmacol 1993; 35: 76P
25. 25. Timmer CJ, Paanakker JE, Van Hal HJM. Pharmacokinetics of mirtazapine from orally administered tablets: influence of gender, age and treatment regimen. Hum Psychopharmacol 1996; 11: 497-509
26. 26. Paanakker JE, Tjepkema S, Timmer CJ. Pharmacokinetics of Org 3770 in young healthy male volunteers after a single oral administration of 30 and 45 mg: dose linearity testing [Study 86020, Report No. 2167]. Oss: N.V. Organon, 1988. (Data on file)
27. 27. Timmer CJ, Paanakker JE, Mink CPA, et al. Assessment of the bioequivalence of four oral Org 3770 formulations (30mg tablet, 15mg tablet, 5mg tablet and 5mg capsule) in healthy, young, male subjects [Study 88003, Report No. 2499]. Oss: N.V. Organon, 1989. (Data on file)
28. 28. Sitsen JMA, Voortman G, Timmer C. Pharmacokinetics of mirtazapine and lithium in healthy male subject. J Clin Psychopharmacol. In press
29. 29. Vrijmoed-De Vries MC, Kleijn HJ, Colbers EPH, et al. Single-dose, fasting, open, two-way cross-over bioequivalence trial on Org 3770 30 mg OraSolv® tablet versus 30 mg Org 3770 marketed tablet in 40 healthy subjects [Study 22527, Report No. NL 0016343]. Oss: N.V. Organon, 1999. (Data on file)
30. 30. Timmer CJ, Paanakker JE, Van Hal HJM. Pharmacokinetics of Org 3770 in young healthy male volunteers after sub-chronic oral administration of escalating daily doses (15-80 mg): dose linearity testing [Study 87003, Report No. 2166]. Oss: N.V. Organon, 1988. (Data on file)
31. 31. Timmer CJ, Lohmann AAM, Mink CPA. Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron® tablets. Hum Psychopharmacol 1995; 10 Suppl.: S97-106
32. 32. Peeters PAM, Brett MA, Van den Heuvel MW. A phase I, multiple dose, pharmacokinetic and safety comparison study of Org 3770 between healthy male Japanese and Caucasian volunteers (Study 22525]. Oss: N.V. Organon, 2000. (Data on file)
33. 33. Timmer CJ, Paanakker JE, Vrijmoed-De Vries M. Mirtazapine pharmacoktnetics with two dosage regimens and two pharmaceutical formulations. Pharm Res 1997; 14: 98-102
34. 34. Mink L, Heftink N, Jonkman JGH, et al. Pharmacokinetics of mirtazapine in combination with amitriptyline. 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31-Nov 4; Paris, 1.039
35. 35. Ebes F, Van Lookeren-Campagne AM, Hartmans HLA, et al. A phase I, single center, single-blind, placebo-controlled multiple dose study of the interaction between Org 3770 and carbamazepine in healthy male volunteers [Study 22514, Report No. NL 0003854]. Oss: N.V. Organon, 1998. (Data on file)
36. 36. Sitsen JMA, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol. In press
37. 37. Van Lookeren-Campagne AM, Hartmans HLA, Ruwe FJL, et al. A phase I, single center, randomized, partially double-blind, multiple dose, three-way cross-over study of the pharmacokinetic and pharmacodynamic interaction of Org 3770 (mirtazapine) and paroxetine in healthy volunteers [Study 22511, Report No. NL 0010166]. Oss: N.V. Organon, 1998. (Data on file)
38. 38. Delbressine LPC, Moonen MEG, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Invest 1998; 15: 45-55
39. 39. Midha K. Biointernational '89. Int Pharm J 4 1990; 3: 101-3
40. 40. Van der Vorstenbosch CG, Delbressine LPC. Binding of Org 3770 to human plasma proteins and human liver proteins [Report No. 2157]. Oss: N.V. Organon, 1988. (Data on file)
41. 41. Vos RME. A pilot study on in vitro binding of Org 3770 to human erythrocytes [Report No. 3384]. Oss: N.V. Organon, 1993. (Data on file)
42. 42. Dahl ML, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest 1997; 13: 37-46
43. 2-receptors. Eur Neuropsychopharmacol 1996; 6 Suppl. 3: 52-3
44. 44. De Graaf JS, Delbressine LPC. Contributions of the enantiomers of mirtazapine (Org 3770) and its demethyl metabolite to its neuropharmacological profile in rats. Eur J Pharmacol 1990; 183; 583-4
45. 45. Mink CPA, Timmer CJ. A single-centre, double-blind, placebo-controlled phase I study in healthy male volunteers to assess the safety, tolerance and pharmacokinetics of intravenously administered Org 3770 [Study 22505. Report No. 3309]. Oss: N.V. Organon, 1993. (Data on file)
46. 46. Simpson GM, Yadalam KG, Levinson DF, et al. Single dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. J Clin Psychophamacol 1990; 10: 417-21
47. 47. Haring C, Meise U, Humpel C, et al. Dose-related plasma levels of clozapine: influence of smoking behavior, sex and age. Psychopharmacology 1989; 99 Suppl. J: S38-40
48. 48. Ereshefsky L, Saklad SR, Watanabe MD, et al. Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 1991; 11: 296-301
49. 49. Hasenack HG, Otjens TCM. Enzyme induction and its reversibility in liver of rats after repeated oral administration of Org 3770 [Report no. 2124]. Oss: N.V. Organon, 1987. (Data on file)
50. 50. Preskorn SH. Selection of an antidepressant: mirtazapine. J Clin Psychiatry 1997; 58 Suppl. 6: 3-8
51. 51. Loonen, AJM, Doorschot CH, Oostelbos MCJM, et al. Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. Eur Neuropsychopharmacol 1999; 10: 51-7
52. 52. Preskorn SH, Omo K, Magnus R, et al. Immediate crossover from fluoxetine to mirtazapine. Biol Psychiatry 1997; 41: 96S
53. 53. Mercer AJ. The effects of ethanol alone and its interactions with other compounds on the dynamics of the saccadic eye movement system [thesis]. Cardiff: Department of Medicine, University of Wales, 1992: 202-55
54. 54. Manila M, Mattila MJ, Vrijmoed-de Vries M, et al. Actions and interactions of psychotropic drugs on human performance and mood: single doses of Org 3770, amitriptyline and diazepam [Study 85148, Report No. 2468]. Oss: N.V. Organon, 1989. (Data on file)
55. 55. Delbressine L, Dahl ML, Van den Wildenberg HM, et al. In vivo study in humans on disposition of the enantiomers and metabolites of mirtazapine [abstract] 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, 1.034
56. 56. De Boer T, Ruigt GSF, Berendsen HHG. The alpha-2-selective adrenoceptor antagonist Org 3770 (Mirtazapine, Remeron) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol 1995; 10 Suppl.: S107-18